Greenlight Biosciences Holdings Pbc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Greenlight Biosciences Holdings Pbc (GRNA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Greenlight Biosciences Holdings Pbc vs Its Competitors
- TTM: Trailing 12-month revenue of 10M vs 60,905M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+47.7% annualized vs trailing 12 months), vs decelerating (-39.4%) for its tracked peer group.
- Growth: Greenlight Biosciences Holdings Pbc generated 1,386.4% revenue growth year over year in Q1 2023, vs -2.2% for its competitors combined.
- Profitability: Its -745.3% net margin compares with 27.0% for the peer group.
- Peer revenue share: Greenlight Biosciences Holdings Pbc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.07M compares with $2.38M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GRNA Sales vs. its Competitors, Q1 2023
Greenlight Biosciences Holdings Pbc reported revenue growth of 1,386.38 % year on year in Q1 2023, above its competitors' combined revenue change of -2.18 %.
With a net margin of -745.26 %, Greenlight Biosciences Holdings Pbc reported lower profitability than its competitors (27.04 %).
Greenlight Biosciences Holdings Pbc generated 0.04 % of the combined sales of its peer group, up from 0.00 % a year earlier.
API endpoints for this dataset
Greenlight Biosciences Holdings Pbc vs. its Competitors, Q1 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Greenlight Biosciences Holdings Pbc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Greenlight Biosciences Holdings Pbc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Greenlight Biosciences Holdings Pbc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Greenlight Biosciences Holdings Pbc's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.9% year over year, combined, vs 1,386.4% for Greenlight Biosciences Holdings Pbc. Greenlight Biosciences Holdings Pbc's share of combined industry revenue moved from 0.00% to 0.01%, a gain of 0.01 percentage points.
Greenlight Biosciences Holdings Pbc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Greenlight Biosciences Holdings Pbc | - | - | - | Yes |
| Competitors combined (27) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GRNA Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Relay Therapeutics Inc | 282.9% | Outperformed |
| 2 | Vor Biopharma Inc | 282.9% | Outperformed |
| 3 | Agenus Inc | 282.9% | Outperformed |
| 4 | Biogen Inc | 282.9% | Outperformed |
| 5 | Zymeworks Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Greenlight Biosciences Holdings Pbc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Greenlight Biosciences Holdings Pbc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Greenlight Biosciences Holdings Pbc |
45.41 | 10.34 |
 Amgen Inc |
255,014.76 | 38,903.00 |
 Argenx Se |
64,796.45 | 8,399.37 |
 Seagen Inc |
43,034.00 | 2,300.35 |
 Biogen Inc |
37,020.94 | 10,297.30 |
 Relay Therapeutics Inc |
3,667.52 | 0.70 |
| SUBTOTAL | 412,125.18 | 60,915.73 |
Sign in to see all competitors of Greenlight Biosciences Holdings Pbc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Greenlight Biosciences Holdings Pbc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Greenlight Biosciences Holdings Pbc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Biogen Inc | Reportable 100.00 % |
| Autolus Therapeutics Plc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Greenlight Biosciences Holdings Pbc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Greenlight Biosciences Holdings Pbc | 45 | 72,329 | -1,100,119 |
| Amgen Inc | 255,015 | 2,992,538 | 722,385 |
| Argenx Se | 64,796 | 7,316,521 | 1,125,466 |
| Seagen Inc | 43,034 | 1,916,959 | -625,187 |
| Biogen Inc | 37,021 | 1,372,973 | 46,333 |
| Relay Therapeutics Inc | 3,668 | 3,620 | -1,489,776 |
| PEERS TOTAL | 412,080 | 2,379,302 | 373,724 |
Sign in to see all peers for Greenlight Biosciences Holdings Pbc.
Greenlight Biosciences Holdings Pbc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Agenus Inc | US 100.00 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Greenlight Biosciences Holdings Pbc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (159 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 35.21 % (avg) | -35.2 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -1.12 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 269.44 % | 8.47 % (avg) | +261.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Greenlight Biosciences Holdings Pbc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (159 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.7x | - |
| EV / EBITDA | - | 16.7x | - |
| P/B | 2.8x | 5.1x | -2.4x |
| Return on Equity | -374.26 % | industry aggregate | -386.50 % |
| Return on Invested Capital | -117.76 % | -11.27 % (avg) | -106.49 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Greenlight Biosciences Holdings Pbc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 269.44 % vs industry average 8.47 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Greenlight Biosciences Holdings Pbc's dedicated Suppliers and Customers pages, not here.
Greenlight Biosciences Holdings Pbc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+47.7% annualized vs trailing 12 months).
Weaknesses
- Return on equity 386.5 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-39.4% annualized).
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: see Methodology: SWOT Analysis.
Greenlight Biosciences Holdings Pbc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Greenlight Biosciences Holdings Pbc | 1.57 | 1.83 | 0.43 |
| Amgen Inc | 0.49 | 1.31 | 5.27 |
| Argenx Se | 2.64 | 5.23 | - |
| Seagen Inc | 0.43 | 3.22 | - |
| Biogen Inc | 0.08 | 2.33 | 0.38 |
| Relay Therapeutics Inc | 3.61 | 20.10 | - |
Sign in to see all peers for Greenlight Biosciences Holdings Pbc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Greenlight Biosciences Holdings Pbc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Greenlight Biosciences Holdings Pbc | Q1 2023 | +1,386.4 % | - |
| Amgen Inc | Q3 2026 | +8.5 % | +20.1 % |
| Argenx Se | Q4 2025 | +89.1 % | +55.1 % |
| Seagen Inc | Q3 2023 | +27.1 % | - |
| Biogen Inc | Q3 2026 | +10.6 % | - |
| Relay Therapeutics Inc | Q2 2026 | -48.3 % | - |
| PEERS TOTAL | +29.0 % | +39.8 % |
Sign in to see all peers for Greenlight Biosciences Holdings Pbc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Greenlight Biosciences Holdings Pbc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Greenlight Biosciences Holdings Pbc | Q1 2023 | - | +460.3 % |
| Amgen Inc | Q3 2026 | -9.5 % | +34.6 % |
| Argenx Se | Q4 2025 | +44.6 % | +242.3 % |
| Seagen Inc | Q3 2023 | +52.8 % | +175.7 % |
| Biogen Inc | Q3 2026 | +11.0 % | -21.6 % |
| Relay Therapeutics Inc | Q2 2026 | - | - |
Sign in to see all peers for Greenlight Biosciences Holdings Pbc.
Greenlight Biosciences Holdings Pbc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Greenlight Biosciences Holdings Pbc | - | - | - |
| Amgen Inc | 10.02% | 13.64% | 85.59% |
| Argenx Se | 14.88% | 14.81% | 17.64% |
| Seagen Inc | - | - | - |
| Biogen Inc | 1.13% | 1.26% | 1.86% |
| Relay Therapeutics Inc | - | - | - |
Sign in to see all peers for Greenlight Biosciences Holdings Pbc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Greenlight Biosciences Holdings Pbc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Greenlight Biosciences Holdings Pbc | - | 4.39 |
| Amgen Inc | 27.08 | 6.56 |
| Argenx Se | 50.14 | 7.71 |
| Seagen Inc | - | 18.71 |
| Biogen Inc | 106.96 | 3.60 |
| Relay Therapeutics Inc | - | 5,277.00 |
| PEERS AVERAGE | 43.80 | 6.77 |
Sign in to see all peers for Greenlight Biosciences Holdings Pbc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.